Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.62 |
| ▸ | PRKCG | P05129 | 6/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.62 |
| ▸ | PRKCB | P05771 | 5/20 | 0.62 |
| ▸ | PRKCH | P24723 | 5/20 | 0.62 |
| ▸ | PRKCI | P41743 | 5/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phorbol SCHEMBL27572795 | 1.00 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL11123948 | 0.91 | PRKCA (0.61) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL7566989 | 0.89 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL29134149 | 0.89 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL20582541 | 0.89 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL417521 | 0.89 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL1893791 | 0.89 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL10620832 | 0.89 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27616694 | 0.89 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL21462215 | 0.89 | PRKCA (0.66) | PRKCAPRKCGPRKD3PRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221005-A1 | METHOD FOR DETECTING ANTIGEN SPECIFIC OR MITOGEN-ACTIVATED T CELLS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2009-09-03 | — | — | US | claimed |
| EP-1996936-A4 | A METHOD FOR DETECTING ANTIGEN-SPECIFIC OR MITOGEN-ACTIVATED T CELLS | ST VINCENTS HOSP SYDNEY (AU) | 2009-04-01 | — | — | EP | claimed |
| EP-1996936-A1 | A METHOD FOR DETECTING ANTIGEN-SPECIFIC OR MITOGEN-ACTIVATED T CELLS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2008-12-03 | — | — | EP | claimed |
| WO-2007106939-A1 | A METHOD FOR DETECTING ANTIGEN-SPECIFIC OR MITOGEN-ACTIVATED T CELLS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2007-09-27 | — | — | WO | claimed |
| US-20050271685-A1 | Cellular permissivity factor for viruses and uses thereof | PHARMACIA AND UPJOHN COMPANY, LLC (US) | 2005-12-08 | — | — | US | claimed |
| US-6355280-B1 | FOR INHIBITING CELLULAR AGING AND FOR PROTECTION OF THE SKIN AGAINST NEGATIVE ENVIRONMENTAL FACTORS AND POLLUTANTS | I.M.S. COSMETICS (IL) | 2002-03-12 | — | — | US | claimed |
| US-20240108673-A1 | BOTANICAL FORMULATIONS | MARY KAY INC. | 2024-04-04 | — | — | US | disclosed |
| US-11912664-B2 | Determining small molecule-protein and protein-protein interactions | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240050505-A1 | BOTANICAL FORMULATIONS | MARY KAY INC. | 2024-02-15 | — | — | US | disclosed |
| WO-2023229891-A1 | NOVEL IMMUNODULATING SMALL MOLECULES | AYUVIS RESEARCH, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-11723954-B2 | Therapeutic and cosmetic uses and applications of calreticulin | NEW YORK UNIVERSITY (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2023086877-A1 | NOVEL COMPOSITIONS AND THERAPEUTIC METHODS | AYUVIS RESEARCH, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11638735-B2 | Botanical formulations | MARY KAY INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-4965195-A | CELL CULTURE; REACTION PRODUCT OF DNA STRAND AND OLIGONUCLEOTIDE | IMMUNEX CORP. (US) | 1990-10-23 | — | — | US | disclosed |
| WO-1989008114-A1 | RAPID IMMUNOSELECTION CLONING METHOD | THE GENERAL HOSPITAL CORPORATION (US) | 1989-09-08 | — | — | WO | disclosed |
| EP-0330191-A2 | DNA encoding CD40 | THE GENERAL HOSPITAL CORPORATION (US) | 1989-08-30 | — | — | EP | disclosed |
| WO-1989003884-A1 | INTERLEUKIN-7 | IMMUNEX CORPORATION (US) | 1989-05-05 | — | — | WO | disclosed |
| EP-0314415-A2 | Interleukin-7 | IMMUNEX CORPORATION (US) | 1989-05-03 | — | — | EP | disclosed |
| WO-1988007854-A1 | NEW ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEM | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1988-10-20 | — | — | WO | disclosed |
| EP-0286418-A1 | Anti-retroviral agents and delivery systems for the same | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912664-B2 | Determining small molecule-protein and protein-protein interactions | MAX, IK, CRYAA | PRKCA 592/4885PRKCG 566/4885PRKD3 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.